

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

ANNOUNCEMENT PROFIT WARNING

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders and potential investors of the Company that, based on the preliminary review of the latest unaudited management accounts of the Group for the year ended 31 December 2023 (the “**FY2023**”) and the information currently available to the Board, the Group is expected to record a significant decrease in net loss of the Group to not more than approximately RMB10 million for FY2023 as compared to the audited consolidated net loss of the Group of approximately RMB1,021 million for the year ended 31 December 2022.

The expected significant decrease in net loss of the Group for FY2023 are primarily attributed to (i) a significant decrease in impairment loss for goodwill and other intangible assets for FY2023; (ii) a reversal of a part of the impairment loss on financial assets; and (iii) a significant decrease in finance costs.

The Group is still in the process of finalizing its audited consolidated results for FY2023. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited management accounts for FY2023 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board. Details of the audited financial performance of the Group will be contained in the annual results announcement of the Group for FY2023, which is expected to be published on 27 March 2024.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Liao Changxiang
Executive Director and Chief Executive Officer

15 March 2024

As at the date of this announcement, the executive Directors are Ms. Liao Changxiang, Ms. Wang Hong and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.